Company news
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) news
Tvardi Therapeutics, Inc. news releases on 6ix. Latest, Aug 14, 2026: Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Press releases & updates
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
August 14, 2026
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
August 12, 2026
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
July 29, 2026
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
July 6, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Events
May 21, 2026
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
May 8, 2026
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
April 1, 2026
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
March 30, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
February 12, 2026
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
January 8, 2026
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 18, 2025
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
November 13, 2025
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
November 4, 2025
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
October 13, 2025
Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
August 21, 2025
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
August 14, 2025
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
July 15, 2025
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
May 27, 2025
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
May 13, 2025
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
May 6, 2025
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
April 13, 2025
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
December 26, 2024
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 17, 2024
Cara Therapeutics Announces Exploration of Strategic Alternatives
July 10, 2024
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
June 11, 2024
Cara Therapeutics Reports First Quarter 2024 Financial Results
May 12, 2024
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
May 5, 2024
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 1, 2024
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
March 6, 2024
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
March 3, 2024
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
February 11, 2024
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
January 21, 2024
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
December 17, 2023
Cara Therapeutics Reports Third Quarter 2023 Financial Results
November 12, 2023
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
November 1, 2023
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
October 22, 2023
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
September 24, 2023
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
Cara Therapeutics Reports Second Quarter 2023 Financial Results
August 6, 2023
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
August 2, 2023
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 1, 2023
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 23, 2023
Cara Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 17, 2023
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 17, 2023
Cara Therapeutics Reports First Quarter 2023 Financial Results
May 14, 2023
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
April 30, 2023
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 9, 2023
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
March 13, 2023